JPM 2023 Sarepta Therapeutics.pdf

《JPM 2023 Sarepta Therapeutics.pdf》由会员分享，可在线阅读，更多相关《JPM 2023 Sarepta Therapeutics.pdf（20页珍藏版）》请在三个皮匠报告上搜索。

1、SAREPTA THERAPEUTICS,INC.2022.ALL RIGHTS RESERVED.1SAREPTA THERAPEUTICS,INC.2023.ALL RIGHTS RESERVED.1Sarepta Therapeutics,Inc.(NASDAQ:SRPT)JPMorgan Healthcare Conference San Francisco,CaliforniaJANUARY 9,2023DOUG INGRAMPresident and CEOSAREPTA THERAPEUTICS,INC.2022.ALL RIGHTS RESERVED.2SAREPTA THER

2、APEUTICS,INC.2023.ALL RIGHTS RESERVED.2FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements.Any statements that are not statements of historical fact may be deemed to be forward-looking statements.Words such as“believe,”“anticipate,”“plan,”“expect,”“will,”“may,”“intend,”“

3、prepare,”“look,”“potential,”“possible”and similar expressions are intended to identify forward-looking statements.These forward-looking statements include statements relating to future operations,financial performance and projections;our current guidance for 2023 for our three currently approved the

4、rapies of more than$925 million in net revenue;our opportunities in the rare disease space;potential solutions and market opportunities with our RNA technologies,gene therapy and gene editing;the potential benefits of our technologies and scientific approaches;the potential benefits of PMO and PPMO;

5、the potentially transformative benefits of SRP-9001,including SRP-9001s potential to transform the trajectory of Duchenne,the potential restoration of DAPC,reduced CK and improved histopathology,and the potential of improved benefit received from SRP-9001 over time;our belief that the 9001-dytsrophi

6、n protein is reasonably likely to predict clinical benefit;our belief that our internal gene therapy capabilities complimented by partnerships will meet demand to launch SRP-9001,if approved,and drive competitive costs with continued improvements to drive upside;our belief that the transformative on